Global Spinal Muscular Atrophy research
Global Spinal Muscular Atrophy research

Spinal Muscular Atrophy Comprehensive Study by Type (Type I, Type II, Type III, Type IV), Application (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Others), Treatment (Gene Therapy, Drug {Spinraza, RG6083 (Olesoxime), RG7916}), Administration Route (Oral, Intrathecal) Players and Region - Global Market Outlook to 2025

Spinal Muscular Atrophy Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Dec 2020 Edition 236 Pages 160 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Spinal Muscular Atrophy Market Overview:
Spinal Muscular Atrophy (SMA) is also known as spinal muscle wasting, spinal amyotrophies, or spinal muscle degeneration. It is a group of inherited diseases that affects the functioning of muscles because of deterioration. SMA leads to the weakness affecting motor neurons present in the brain & spinal cord and may even result to death. The muscle weakness usually worsens with age. As per the survey, spinal muscular atrophy affects 1 per 8,000 to 10,000 people worldwide. Spinal muscular atrophy type I is the most common type, accounting for about half of all cases followed by Type II and Type III. Although it is not currently possible to cure spinal muscular atrophy, but ongoing research is to find new treatments is expected to open new opportunities fir the market in coming years. Spinal Muscular Atrophy (SMA) is also known as spinal muscle wasting, spinal amyotrophies, or spinal muscle degeneration. It is a group of inherited diseases that affects the functioning of muscles because of deterioration. SMA leads to the weakness affecting motor neurons present in the brain & spinal cord and may even result to death. The muscle weakness usually worsens with age. As per the survey, spinal muscular atrophy affects 1 per 8,000 to 10,000 people worldwide. Spinal muscular atrophy type I is the most common type, accounting for about half of all cases followed by Type II and Type III. Although it is not currently possible to cure spinal muscular atrophy, but ongoing research is to find new treatments is expected to open new opportunities fir the market in coming years.

Growth Drivers
  • Growing Adoption Of Spinraza
  • Increasing Spinal Muscular Atrophy Cases In Children

Market Trends
  • Advances In Diagnostic Techniques

Roadblocks
  • Limited Access To Spinal Muscular Atrophy Treatment

Opportunities
  • Increasing Awareness About Spinal Muscular Atrophy Due to Initiatives Undertaken By Government and Nonprofit, Organizations
  • Opportunities from Untapped Countries

Challenges
  • Unavailability of Regulations for Spinal Muscular Atrophy Treatments


Competitive Landscape:
The market appears to be highly concentrated and only Biogen has approved drugs for spinal muscular atrophy treatment. However, it is expected that new players will be entering the market during the forecast period. The increase in the development of new innovative therapies and investment in R& D by companies will increase the competition level in the forecast period.
Some of the key players profiled in the report are Biogen Idec (United States), Pfizer (United States), Isis Pharmaceuticals (United States), Boehringer Ingelheim (Germany), F. Hoffmann-La Roche (Switzerland) and Regeneron Pharmaceuticals (United States). Analyst at AMA Research see United States and European Players to retain maximum share of Global Spinal Muscular Atrophy market by 2025. Considering Market by Treatment, the sub-segment i.e. Gene Therapy will boost the Spinal Muscular Atrophy market. Considering Market by Administration Route, the sub-segment i.e. Oral will boost the Spinal Muscular Atrophy market.

In August 2020, FDA approved Roche’s Spinal Muscular Atrophy Drug named Risdiplam (Evrysdi), a first oral therapy drug. Evrysdi is the first drug for spinal muscular atrophy disease that can be taken orally.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Spinal Muscular Atrophy market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Spinal Muscular Atrophy market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Spinal Muscular Atrophy Providers, Venture Capitalists, Private Equity Firms, Government Regulatory, Research Organizations and End Users.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Type I
  • Type II
  • Type III
  • Type IV
By Application
  • Hospitals
  • Ambulatory Surgical Centers
  • Diagnostic Centers
  • Others
By Treatment
  • Gene Therapy
  • Drug {Spinraza, RG6083 (Olesoxime), RG7916}

By Administration Route
  • Oral
  • Intrathecal

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Adoption Of Spinraza
      • 3.2.2. Increasing Spinal Muscular Atrophy Cases In Children
    • 3.3. Market Challenges
      • 3.3.1. Unavailability of Regulations for Spinal Muscular Atrophy Treatments
    • 3.4. Market Trends
      • 3.4.1. Advances In Diagnostic Techniques
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Spinal Muscular Atrophy, by Type, Application, Treatment, Administration Route and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Spinal Muscular Atrophy (Value)
      • 5.2.1. Global Spinal Muscular Atrophy by: Type (Value)
        • 5.2.1.1. Type I
        • 5.2.1.2. Type II
        • 5.2.1.3. Type III
        • 5.2.1.4. Type IV
      • 5.2.2. Global Spinal Muscular Atrophy by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Ambulatory Surgical Centers
        • 5.2.2.3. Diagnostic Centers
        • 5.2.2.4. Others
      • 5.2.3. Global Spinal Muscular Atrophy by: Treatment (Value)
        • 5.2.3.1. Gene Therapy
        • 5.2.3.2. Drug {Spinraza, RG6083 (Olesoxime), RG7916}
      • 5.2.4. Global Spinal Muscular Atrophy by: Administration Route (Value)
        • 5.2.4.1. Oral
        • 5.2.4.2. Intrathecal
      • 5.2.5. Global Spinal Muscular Atrophy Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Spinal Muscular Atrophy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Biogen Idec (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Isis Pharmaceuticals (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Boehringer Ingelheim (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. F. Hoffmann-La Roche (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Regeneron Pharmaceuticals (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
  • 7. Global Spinal Muscular Atrophy Sale, by Type, Application, Treatment, Administration Route and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Spinal Muscular Atrophy (Value)
      • 7.2.1. Global Spinal Muscular Atrophy by: Type (Value)
        • 7.2.1.1. Type I
        • 7.2.1.2. Type II
        • 7.2.1.3. Type III
        • 7.2.1.4. Type IV
      • 7.2.2. Global Spinal Muscular Atrophy by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Ambulatory Surgical Centers
        • 7.2.2.3. Diagnostic Centers
        • 7.2.2.4. Others
      • 7.2.3. Global Spinal Muscular Atrophy by: Treatment (Value)
        • 7.2.3.1. Gene Therapy
        • 7.2.3.2. Drug {Spinraza, RG6083 (Olesoxime), RG7916}
      • 7.2.4. Global Spinal Muscular Atrophy by: Administration Route (Value)
        • 7.2.4.1. Oral
        • 7.2.4.2. Intrathecal
      • 7.2.5. Global Spinal Muscular Atrophy Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Spinal Muscular Atrophy: by Type(USD Million)
  • Table 2. Spinal Muscular Atrophy Type I , by Region USD Million (2014-2019)
  • Table 3. Spinal Muscular Atrophy Type II , by Region USD Million (2014-2019)
  • Table 4. Spinal Muscular Atrophy Type III , by Region USD Million (2014-2019)
  • Table 5. Spinal Muscular Atrophy Type IV , by Region USD Million (2014-2019)
  • Table 6. Spinal Muscular Atrophy: by Application(USD Million)
  • Table 7. Spinal Muscular Atrophy Hospitals , by Region USD Million (2014-2019)
  • Table 8. Spinal Muscular Atrophy Ambulatory Surgical Centers , by Region USD Million (2014-2019)
  • Table 9. Spinal Muscular Atrophy Diagnostic Centers , by Region USD Million (2014-2019)
  • Table 10. Spinal Muscular Atrophy Others , by Region USD Million (2014-2019)
  • Table 11. Spinal Muscular Atrophy: by Treatment(USD Million)
  • Table 12. Spinal Muscular Atrophy Gene Therapy , by Region USD Million (2014-2019)
  • Table 13. Spinal Muscular Atrophy Drug {Spinraza, RG6083 (Olesoxime), RG7916} , by Region USD Million (2014-2019)
  • Table 14. Spinal Muscular Atrophy: by Administration Route(USD Million)
  • Table 15. Spinal Muscular Atrophy Oral , by Region USD Million (2014-2019)
  • Table 16. Spinal Muscular Atrophy Intrathecal , by Region USD Million (2014-2019)
  • Table 17. South America Spinal Muscular Atrophy, by Country USD Million (2014-2019)
  • Table 18. South America Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 19. South America Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 20. South America Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 21. South America Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 22. Brazil Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 23. Brazil Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 24. Brazil Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 25. Brazil Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 26. Argentina Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 27. Argentina Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 28. Argentina Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 29. Argentina Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 30. Rest of South America Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 31. Rest of South America Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 32. Rest of South America Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 33. Rest of South America Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 34. Asia Pacific Spinal Muscular Atrophy, by Country USD Million (2014-2019)
  • Table 35. Asia Pacific Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 36. Asia Pacific Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 37. Asia Pacific Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 38. Asia Pacific Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 39. China Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 40. China Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 41. China Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 42. China Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 43. Japan Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 44. Japan Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 45. Japan Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 46. Japan Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 47. India Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 48. India Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 49. India Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 50. India Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 51. South Korea Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 52. South Korea Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 53. South Korea Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 54. South Korea Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 55. Taiwan Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 56. Taiwan Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 57. Taiwan Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 58. Taiwan Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 59. Australia Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 60. Australia Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 61. Australia Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 62. Australia Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 63. Rest of Asia-Pacific Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 64. Rest of Asia-Pacific Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 65. Rest of Asia-Pacific Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 66. Rest of Asia-Pacific Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 67. Europe Spinal Muscular Atrophy, by Country USD Million (2014-2019)
  • Table 68. Europe Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 69. Europe Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 70. Europe Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 71. Europe Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 72. Germany Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 73. Germany Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 74. Germany Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 75. Germany Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 76. France Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 77. France Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 78. France Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 79. France Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 80. Italy Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 81. Italy Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 82. Italy Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 83. Italy Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 84. United Kingdom Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 85. United Kingdom Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 86. United Kingdom Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 87. United Kingdom Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 88. Netherlands Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 89. Netherlands Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 90. Netherlands Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 91. Netherlands Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 92. Rest of Europe Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 93. Rest of Europe Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 94. Rest of Europe Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 95. Rest of Europe Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 96. MEA Spinal Muscular Atrophy, by Country USD Million (2014-2019)
  • Table 97. MEA Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 98. MEA Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 99. MEA Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 100. MEA Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 101. Middle East Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 102. Middle East Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 103. Middle East Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 104. Middle East Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 105. Africa Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 106. Africa Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 107. Africa Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 108. Africa Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 109. North America Spinal Muscular Atrophy, by Country USD Million (2014-2019)
  • Table 110. North America Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 111. North America Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 112. North America Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 113. North America Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 114. United States Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 115. United States Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 116. United States Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 117. United States Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 118. Canada Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 119. Canada Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 120. Canada Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 121. Canada Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 122. Mexico Spinal Muscular Atrophy, by Type USD Million (2014-2019)
  • Table 123. Mexico Spinal Muscular Atrophy, by Application USD Million (2014-2019)
  • Table 124. Mexico Spinal Muscular Atrophy, by Treatment USD Million (2014-2019)
  • Table 125. Mexico Spinal Muscular Atrophy, by Administration Route USD Million (2014-2019)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Spinal Muscular Atrophy: by Type(USD Million)
  • Table 133. Spinal Muscular Atrophy Type I , by Region USD Million (2020-2025)
  • Table 134. Spinal Muscular Atrophy Type II , by Region USD Million (2020-2025)
  • Table 135. Spinal Muscular Atrophy Type III , by Region USD Million (2020-2025)
  • Table 136. Spinal Muscular Atrophy Type IV , by Region USD Million (2020-2025)
  • Table 137. Spinal Muscular Atrophy: by Application(USD Million)
  • Table 138. Spinal Muscular Atrophy Hospitals , by Region USD Million (2020-2025)
  • Table 139. Spinal Muscular Atrophy Ambulatory Surgical Centers , by Region USD Million (2020-2025)
  • Table 140. Spinal Muscular Atrophy Diagnostic Centers , by Region USD Million (2020-2025)
  • Table 141. Spinal Muscular Atrophy Others , by Region USD Million (2020-2025)
  • Table 142. Spinal Muscular Atrophy: by Treatment(USD Million)
  • Table 143. Spinal Muscular Atrophy Gene Therapy , by Region USD Million (2020-2025)
  • Table 144. Spinal Muscular Atrophy Drug {Spinraza, RG6083 (Olesoxime), RG7916} , by Region USD Million (2020-2025)
  • Table 145. Spinal Muscular Atrophy: by Administration Route(USD Million)
  • Table 146. Spinal Muscular Atrophy Oral , by Region USD Million (2020-2025)
  • Table 147. Spinal Muscular Atrophy Intrathecal , by Region USD Million (2020-2025)
  • Table 148. South America Spinal Muscular Atrophy, by Country USD Million (2020-2025)
  • Table 149. South America Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 150. South America Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 151. South America Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 152. South America Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 153. Brazil Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 154. Brazil Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 155. Brazil Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 156. Brazil Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 157. Argentina Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 158. Argentina Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 159. Argentina Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 160. Argentina Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 161. Rest of South America Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 162. Rest of South America Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 163. Rest of South America Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 164. Rest of South America Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 165. Asia Pacific Spinal Muscular Atrophy, by Country USD Million (2020-2025)
  • Table 166. Asia Pacific Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 167. Asia Pacific Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 168. Asia Pacific Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 169. Asia Pacific Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 170. China Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 171. China Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 172. China Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 173. China Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 174. Japan Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 175. Japan Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 176. Japan Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 177. Japan Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 178. India Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 179. India Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 180. India Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 181. India Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 182. South Korea Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 183. South Korea Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 184. South Korea Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 185. South Korea Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 186. Taiwan Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 187. Taiwan Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 188. Taiwan Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 189. Taiwan Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 190. Australia Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 191. Australia Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 192. Australia Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 193. Australia Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 194. Rest of Asia-Pacific Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 195. Rest of Asia-Pacific Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 196. Rest of Asia-Pacific Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 197. Rest of Asia-Pacific Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 198. Europe Spinal Muscular Atrophy, by Country USD Million (2020-2025)
  • Table 199. Europe Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 200. Europe Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 201. Europe Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 202. Europe Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 203. Germany Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 204. Germany Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 205. Germany Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 206. Germany Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 207. France Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 208. France Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 209. France Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 210. France Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 211. Italy Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 212. Italy Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 213. Italy Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 214. Italy Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 215. United Kingdom Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 216. United Kingdom Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 217. United Kingdom Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 218. United Kingdom Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 219. Netherlands Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 220. Netherlands Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 221. Netherlands Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 222. Netherlands Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 223. Rest of Europe Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 224. Rest of Europe Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 225. Rest of Europe Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 226. Rest of Europe Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 227. MEA Spinal Muscular Atrophy, by Country USD Million (2020-2025)
  • Table 228. MEA Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 229. MEA Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 230. MEA Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 231. MEA Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 232. Middle East Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 233. Middle East Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 234. Middle East Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 235. Middle East Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 236. Africa Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 237. Africa Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 238. Africa Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 239. Africa Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 240. North America Spinal Muscular Atrophy, by Country USD Million (2020-2025)
  • Table 241. North America Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 242. North America Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 243. North America Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 244. North America Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 245. United States Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 246. United States Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 247. United States Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 248. United States Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 249. Canada Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 250. Canada Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 251. Canada Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 252. Canada Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 253. Mexico Spinal Muscular Atrophy, by Type USD Million (2020-2025)
  • Table 254. Mexico Spinal Muscular Atrophy, by Application USD Million (2020-2025)
  • Table 255. Mexico Spinal Muscular Atrophy, by Treatment USD Million (2020-2025)
  • Table 256. Mexico Spinal Muscular Atrophy, by Administration Route USD Million (2020-2025)
  • Table 257. Research Programs/Design for This Report
  • Table 258. Key Data Information from Secondary Sources
  • Table 259. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Spinal Muscular Atrophy: by Type USD Million (2014-2019)
  • Figure 5. Global Spinal Muscular Atrophy: by Application USD Million (2014-2019)
  • Figure 6. Global Spinal Muscular Atrophy: by Treatment USD Million (2014-2019)
  • Figure 7. Global Spinal Muscular Atrophy: by Administration Route USD Million (2014-2019)
  • Figure 8. South America Spinal Muscular Atrophy Share (%), by Country
  • Figure 9. Asia Pacific Spinal Muscular Atrophy Share (%), by Country
  • Figure 10. Europe Spinal Muscular Atrophy Share (%), by Country
  • Figure 11. MEA Spinal Muscular Atrophy Share (%), by Country
  • Figure 12. North America Spinal Muscular Atrophy Share (%), by Country
  • Figure 13. Global Spinal Muscular Atrophy share by Players 2019 (%)
  • Figure 14. Global Spinal Muscular Atrophy share by Players (Top 3) 2019(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Biogen Idec (United States) Revenue, Net Income and Gross profit
  • Figure 17. Biogen Idec (United States) Revenue: by Geography 2019
  • Figure 18. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer (United States) Revenue: by Geography 2019
  • Figure 20. Isis Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 21. Isis Pharmaceuticals (United States) Revenue: by Geography 2019
  • Figure 22. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Boehringer Ingelheim (Germany) Revenue: by Geography 2019
  • Figure 24. F. Hoffmann-La Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. F. Hoffmann-La Roche (Switzerland) Revenue: by Geography 2019
  • Figure 26. Regeneron Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 27. Regeneron Pharmaceuticals (United States) Revenue: by Geography 2019
  • Figure 28. Global Spinal Muscular Atrophy: by Type USD Million (2020-2025)
  • Figure 29. Global Spinal Muscular Atrophy: by Application USD Million (2020-2025)
  • Figure 30. Global Spinal Muscular Atrophy: by Treatment USD Million (2020-2025)
  • Figure 31. Global Spinal Muscular Atrophy: by Administration Route USD Million (2020-2025)
  • Figure 32. South America Spinal Muscular Atrophy Share (%), by Country
  • Figure 33. Asia Pacific Spinal Muscular Atrophy Share (%), by Country
  • Figure 34. Europe Spinal Muscular Atrophy Share (%), by Country
  • Figure 35. MEA Spinal Muscular Atrophy Share (%), by Country
  • Figure 36. North America Spinal Muscular Atrophy Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Biogen Idec (United States)
  • Pfizer (United States)
  • Isis Pharmaceuticals (United States)
  • Boehringer Ingelheim (Germany)
  • F. Hoffmann-La Roche (Switzerland)
  • Regeneron Pharmaceuticals (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation